Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Aida Pharma Acquires Jiangsu Institute

publication date: Mar 27, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Aida Pharmaceuticals will obtain a controlling interest in Jiangsu Institute of Microbiology Co., Ltd. (JSIM), a research institute with several products on the market and several more in clinical trials. Aida did not release details about the company’s offerings or JSIM’s research focus. Aida is attempting to diversify its pharmaceutical offerings away from a heavy dependence on its antibiotic, Etimicin, which was the source of 69% of its revenues during the first nine months of 2007. More details...

Stock Symbol: (OTCBB: AIDA)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...